Pharmacologic Considerations in the Young Patient

CHAPTER 27 Pharmacologic Considerations in the Young Patient

Treatment of neonates in small animal medicine presents challenges for clinicians because of the marked anatomic and physiologic differences between puppies and kittens and adult animals. Current guidelines for the treatment of puppies and kittens have been extrapolated from other species, including human neonates, and from a small number of studies. Therefore many of the recommendations in this chapter are provided to make practitioners aware of pharmacological considerations that may require dosage adjustments in young animals.

Drug Absorption

Puppies and kittens can be exposed to drugs in utero through placental transfer. Neonates can also be exposed by ingesting compounds in their mother’s milk during nursing or through direct administration. Each source of exposure can be problematic for a developing fetus or a young animal because of differences in proportions and physiology compared with more mature animals. Although current veterinary drug reference handbooks provide little guidance for administration of medications to young animals, there are some basic considerations that are helpful for clinicians when administering drugs to pregnant or nursing mothers and young puppies or kittens.

Oral Absorption

Within the absorptive region of the neonatal small intestine, the surface area is sufficiently large relative to the size of the animal to allow a highly bioavailable drug to be rapidly absorbed. This absorption may lead to higher-than-anticipated peak plasma drug concentrations after oral administration of a medication. The increase in the rate of absorption combined with increased intestinal permeability in young animals can produce plasma concentrations that may reach toxic levels with some drugs. Drugs that normally have limited oral bioavailability can reach systemic circulation in the neonatal animal. These drugs include aminoglycosides, carbenicillin (and other acid-sensitive beta-lactams), and enteric sulfonamides. However, the practitioner should also consider other factors that may limit absorption of drugs in puppies and kittens. For example, intestinal permeability will be substantially reduced after the ingestion of colostrum or exogenous supplementation of either hydrocortisone or adrenocorticotropic hormone (ACTH) in the mother before giving birth.

Very young animals also have decreased gastric emptying time and irregular peristalsis that can partially protect against the increase in maximum systemic drug concentrations. Decreased gastric emptying in young dogs has been observed in multiple breeds, independent of size. Reduced gastric emptying may decrease the likelihood of reaching toxic drug concentrations by slowing the rate of absorption and thus reducing peak plasma concentrations. However, gastric emptying time has been shown to be shorter in puppies 12 weeks of age compared to older animals, so it may not be prudent to assume that decreased gastric emptying time will provide protection from high peak plasma concentrations. As a puppy develops, the rate increases to become higher than would be expected in an adult animal. This means that the practitioner should be aware that oral drugs with a narrow therapeutic index may present a problem for neonates, particularly when toxicity occurs because of peak plasma concentrations. Further, the practitioner must consider that if the peak concentration is reduced because of gastric emptying time, the net effect may result in increased steady-state plasma concentration and a reduced dose or dosing interval may be warranted.

Gastric pH is also a consideration for oral administration of drugs to newborns. Although pH in adult animals is quite acidic, the pH of newborns is closer to neutral. Mean gastric pH has been found to be stable at 5.85 until the seventh day of life. After day 7, gastric pH was shown to decrease to 3.45 and then increase to a mean of 4.95 through the eighteenth day. These types of changes will likely affect absorption of mildly acidic or basic drugs and either limit or increase bioavailability depending on pKa. For example, when pH is less acidic, drugs, such as beta-lactam antibiotics (weak acids), will be ionized and thus less bioavailable. Also, high gastric pH may decrease the bioavailability of drugs, such as ketoconazole and itraconazole, that require an acid environment for absorption. In contrast, weak bases, including the aminoglycoside antibiotics and fluconazole, have greater bioavailability. It is ultimately up to the practitioner to weigh the margin of safety versus the likelihood that the drug absorption might be significantly different from that expected in the adult.

A consideration for giving medications to nursing puppies and kittens includes the reduced absorption of concomitant administration of drug when milk may be present in the stomach. Milk can both decrease gastric emptying time and may also interact with drugs directly. Drugs likely to have reduced bioavailability include enrofloxacin and doxycycline. These interactions may lead to reduced absorption and result in lower peak plasma concentrations.

Newborn puppies and kittens can also be expected to have reduced hepatobiliary function, reduced capacity for drug metabolism through the cytochrome P-450 system, and reduced glucuronidation up to 4 to 6 weeks of age. These differences in phase I and II metabolism tend to lower absorption of fat-soluble drugs and vitamins. Also, reduced metabolism reduces the clearance of some drugs, including lidocaine and theophylline, that rely on P-450 metabolism. Other drugs, including morphine and many NSAIDs, may have reduced clearance as a result of reduced glucuronidation. Neonatal puppies and kittens also require time for their intestinal flora to be fully colonized; therefore an altered response to drugs that require activation in the intestine can be expected.

Drug Distribution

One obvious difference between neonates and adult animals is the difference in proportion of head-to-body sizes. Body weight is also distributed differently in puppies and kittens, and these differences lead to changes that can present challenges to drug therapy. For example, the proportion of extracellular fluid as a percentage of total body weight changes significantly during the life of a maturing puppy. As seen in Figure 27-1, the changes occurring in the growing puppy (and similarly in the kitten) are a result of the total water alterations as a proportion of body weight. This water is found primarily in the extracellular fluid compared to percent intracellular fluid and will have significant effects on the absorption and distribution of drugs within the animal, including decreased plasma concentrations and longer half-lives. Plasma concentrations of water-soluble compounds are lower in pediatric patients compared with adults because the volume into which the compound is distributed is greater in the young. Unbound lipid-soluble compounds have the same type of distribution because they are distributed into the total body of water.

A second factor important to the distribution of lipid-soluble drugs is the relative lack of fat in neonates and puppies compared to adult animals. Because fat acts as a reservoir for many lipid-soluble drugs, the absence of significant fat stores results in higher plasma concentrations of these types of drugs.

A number of biologic functions are reduced in young animals and will contribute to differences in drug distribution compared to adult animals. Hepatic gluconeogenesis, glycogenolysis, protein synthesis, and bile acid metabolism are reduced in neonates, with adult values occurring after 8 weeks of age. These decreases can contribute to the changes observed in drug metabolism and will alter the distribution of drugs that are protein bound in the circulation.

Drug Responses

Adverse responses to drugs and drug formulations are more likely in puppies and kittens than in their adult counterparts. For example, administration of a drug formulation likely to cause a large shift in osmolality can result in a number of clinically significant adverse effects. Intravenous (IV) administration of hypertonic solutions containing sodium bicarbonate and radiocontrast materials in young animals can result in intraventricular hemorrhage and necrotizing enterocolitis.

Although pharmacokinetic differences contribute significantly to therapeutic failure in puppies and kittens, pharmacodynamic differences are also important to drug response in this population. A lack of response from drugs, such as atropine, isoproterenol, dopamine, and dobutamine, as well as anticholinergic drugs, has been demonstrated. The lack of drug response may be due in part to the immaturity of innervation in the developing animal.

There is relatively little information on the risks to the fetus associated with giving medications during pregnancy; much of the information available is limited to human medicine. However, there are some general guidelines that have been developed that may be helpful in assessing the impact of drug therapy in this population. Table 27-3 shows drug categories and a description of the effects of the different categories. Table 27-4 lists the general safety of a variety of drugs for use in neonates.

TABLE 27-3 Drug category and description of effects

Drug category Description
A Adequate, well-controlled studies in pregnant women have not shown an increased risk of fetal abnormalities.

Stay updated, free articles. Join our Telegram channel

Sep 11, 2016 | Posted by in SMALL ANIMAL | Comments Off on Pharmacologic Considerations in the Young Patient

Full access? Get Clinical Tree

Get Clinical Tree app for offline access